report
experi
acut
interstiti
pneumonia
aip
patient
underw
earli
diagnost
procedur
receiv
mechan
ventil
lungprotect
strategi
earli
institut
immunosuppress
therapi
design
retrospect
chart
review
set
tertiari
referr
hospit
particip
ten
patient
aip
present
idiopath
ard
show
diffus
alveolar
damag
surgic
lung
biopsi
specimen
juli
march
measur
result
median
age
patient
year
age
rang
year
patient
present
median
durat
sever
dyspnea
day
rang
day
hospit
visit
patient
requir
mechan
ventil
begin
median
time
hospit
day
rang
hospit
day
continu
median
durat
day
rang
day
patient
receiv
ventil
pressur
assistcontrol
mode
median
tidal
volum
mlkg
rang
mlkg
median
posit
endexpiratori
pressur
cm
h
rang
cm
h
aggress
diagnost
workup
respiratori
infect
includ
bal
median
time
hospit
day
rang
hospit
day
perform
highdos
steroid
puls
therapi
initi
median
hospit
day
rang
hospit
day
surgic
lung
biopsi
perform
median
hospit
day
rang
hospit
day
eight
patient
surviv
hospit
discharg
conclus
earlier
intervent
aggress
diagnost
approach
mechan
ventil
lungprotect
strategi
earli
institut
immunosuppress
may
improv
clinic
outcom
patient
aip
abbrevi
aip
acut
interstiti
pneumonia
apach
acut
physiolog
chronic
health
evalu
dad
diffus
alveolar
damag
fio
fraction
inspir
oxygen
hrct
highresolut
ct
peep
posit
endexpiratori
pressur
cute
interstiti
pneumonia
aip
distinct
clinicopatholog
entiti
diagnos
clinic
featur
ard
unknown
etiolog
patholog
find
diffus
alveolar
damag
dad
lung
biopsi
specimen
sinc
first
report
hamman
rich
sever
case
seri
aip
publish
literatur
accord
report
uncommon
diseas
character
rapid
develop
acut
respiratori
failur
previous
healthi
individu
high
mortal
despit
intens
treatment
includ
mechan
ventil
howev
report
aip
show
higher
surviv
rate
suggest
aip
might
fatal
diseas
date
guidelin
manag
aip
publish
patient
aip
usual
requir
mechan
ventil
receiv
therapi
corticosteroid
unclear
whether
treatment
effect
patient
aip
institut
take
aggress
diagnost
therapeut
approach
patient
suspect
aip
includ
prompt
investig
respiratori
infect
potenti
etiolog
ard
applic
mechan
ventil
lungprotect
strategi
rapid
confirmatori
diagnosi
dad
surgic
lung
biopsi
earli
initi
highdos
puls
steroid
therapi
approach
result
surprisingli
high
surviv
rate
patient
aip
report
experi
juli
march
surgic
lung
biopsi
perform
diagnost
purpos
patient
interstiti
lung
diseas
unexplain
bilater
lung
infiltr
samsung
medic
center
among
patient
found
patholog
diagnosi
dad
intern
review
board
approv
chart
review
obtain
inform
consent
waiv
due
retrospect
natur
studi
medic
record
patholog
find
patient
review
diagnos
aip
diagnost
criteria
aip
follow
acut
respiratori
failur
develop
within
month
presenc
dad
surgic
lung
biopsi
specimen
absenc
underli
chronic
pulmonari
diseas
previous
abnorm
chest
radiograph
find
absenc
known
incit
event
predispos
condit
ard
respiratori
infect
collagen
vascular
diseas
exposur
environment
occup
toxic
agent
drug
radiat
prior
interstiti
lung
diseas
recent
histori
shock
use
vasopressor
prior
hospit
admiss
follow
review
medic
record
case
patient
exclud
studi
known
caus
dad
etiolog
dad
infect
n
drug
n
collagen
vascular
diseas
n
acut
exacerb
usual
interstiti
pneumonia
n
other
n
patholog
slide
remain
patient
dad
review
two
experienc
lung
pathologist
jh
mk
lung
pathologist
concur
diagnosi
case
exclud
analysi
altern
histopatholog
diagnosi
suggest
one
pathologist
three
case
bronchiol
obliteran
organ
pneumonia
two
patient
nonspecif
interstiti
pneumonia
one
patient
thu
initi
patient
show
presenc
dad
surgic
lung
biopsi
specimen
patient
determin
definit
aip
case
includ
final
analysi
clinic
laboratori
paramet
age
sex
durat
symptom
respir
rate
bodi
temperatur
acut
physiolog
chronic
health
evalu
apach
ii
score
arteri
blood
ga
analysi
presenc
organ
failur
retrospect
obtain
expert
chest
radiologist
analyz
highresolut
ct
hrct
scan
chest
extent
groundglass
opac
consolid
reticul
nodul
distribut
condit
classifi
diffus
pattern
patchi
pattern
extent
pattern
parenchym
abnorm
estim
nearest
lung
volum
differ
pattern
distribut
abnorm
survivor
nonsurvivor
compar
lung
specimen
classifi
exud
prolif
mix
exud
prolif
phase
dad
presenc
mark
architectur
distort
also
evalu
data
shown
median
valu
rang
unless
otherwis
indic
differ
clinic
paramet
survivor
nonsurvivor
compar
fisher
exact
test
wilcoxon
rank
sum
test
appropri
median
age
patient
year
rang
year
tabl
four
femal
patient
six
male
patient
patient
present
sever
dyspnea
fever
patient
cough
patient
whitish
sputum
patient
durat
symptom
prior
hospit
visit
day
rang
day
patient
treat
empir
antibiot
idea
communityacquir
pneumonia
fail
respond
therapi
time
visit
hospit
patient
tachypn
respir
rate
breathsmin
rang
breathsmin
apach
ii
score
rang
patient
evid
organ
failur
except
respiratori
system
pao
fraction
inspir
oxygen
fio
ratio
rang
posit
endexpiratori
pressur
peep
cm
h
rang
cm
h
day
surgic
lung
biopsi
perform
patient
immedi
admit
medic
icu
therapi
iv
empir
antibiot
administ
consist
american
thorac
societi
guidelin
manag
sever
communityacquir
pneumonia
blood
sputum
cultur
serolog
atyp
pneumonia
bal
hospit
day
rang
hospit
day
exclud
respiratori
infect
perform
patient
mechan
ventil
start
day
rang
day
continu
day
rang
day
wean
ventil
death
patient
initi
receiv
ventil
pressur
assistcontrol
mode
peep
cm
h
rang
cm
h
tidal
volum
ml
per
measur
bodi
weight
rang
ml
surgic
lung
biopsi
minithoracotomi
perform
gener
anesthesia
undertaken
day
rang
day
highdos
steroid
puls
therapi
initi
day
rang
day
antiinflammatori
therapi
consist
gd
iv
methylprednisolon
consecut
day
follow
mgkgd
iv
methylprednisolon
oral
prednisolon
week
subsequ
gradual
taper
total
durat
corticosteroid
therapi
survivor
day
rang
day
despit
aggress
manag
two
patient
patient
die
worsen
respiratori
failur
day
day
respect
condit
eight
patient
improv
success
wean
ventil
median
durat
mechan
ventil
survivor
day
rang
day
age
respir
rate
apach
ii
score
time
hospit
admiss
onset
symptom
time
surgic
lung
biopsi
onset
symptom
time
initi
corticosteroid
therapi
onset
symptom
differ
survivor
nonsurvivor
p
eight
survivor
follow
median
durat
month
rang
month
one
patient
patient
need
mechan
ventil
day
success
wean
ventil
develop
slowli
progress
lung
fibrosi
eventu
die
pneumonia
month
later
remain
seven
patient
asymptomat
without
show
recurr
diseas
signific
residu
lung
fibrosi
followup
posteroanterior
chest
radiograph
hrct
scan
diffus
bilater
lung
hazi
note
initi
plain
chest
radiograph
patient
main
abnorm
seen
initi
hrct
scan
median
day
rang
day
groundglass
opac
patient
airspac
consolid
patient
bilater
pleural
effus
patient
reticul
patient
nodul
patient
also
seen
honeycomb
absent
total
extent
lung
involv
calcul
rang
groundglass
opac
compris
rang
consolid
compris
rang
tabl
differ
total
extent
lung
involv
extent
specif
lung
lesion
survivor
nonsurvivor
p
although
pattern
multifoc
patchi
consolid
seen
nonsurvivor
patient
fig
bottom
left
e
bottom
right
f
also
note
two
survivor
patient
contrari
pattern
diffus
bilater
white
lung
groundglass
opac
chest
hrct
scan
seen
rest
surviv
patient
fig
top
left
bottom
right
f
note
two
nonsurvivor
one
patient
patient
eventu
die
show
markedli
increas
volum
interstitium
due
myofibroblast
prolifer
sever
architectur
distort
enlarg
alveolar
space
also
found
promin
hyalin
membran
format
activ
fibrin
exud
alveoli
suggest
activ
lung
injuri
ongo
sever
fibrosi
comparison
seven
patient
surviv
exud
phase
dad
uniform
distribut
n
mix
exud
prolif
phase
dad
somewhat
patchi
distribut
n
mix
exud
prolif
phase
dad
airway
organ
n
none
survivor
show
architectur
distort
case
chronic
fibrot
phase
dad
found
studi
retrospect
studi
suggest
rapid
confirmatori
diagnosi
earli
therapeut
intervent
may
increas
surviv
patient
aip
outlin
diagnost
therapeut
approach
quit
decis
appropri
cultur
serolog
microbi
agent
perform
median
day
institut
empir
antibiot
recommend
american
thorac
societi
patient
eventu
warrant
mechan
ventil
lungprotect
strategi
bal
perform
median
day
infect
deem
unlik
highdos
steroid
puls
therapi
start
median
day
confirm
diagnosi
aip
surgic
lung
biopsi
perform
median
day
aggress
diagnost
therapeut
approach
patient
aip
surviv
hospit
discharg
although
present
acut
lung
injuryard
indic
rapid
respir
rate
low
pao
fio
ratio
need
mechan
ventil
patient
high
surviv
rate
patient
sharpli
contrast
rate
earli
report
aip
patient
similar
rate
recent
report
tabl
report
mortal
rate
patient
aip
high
rang
even
studi
vourleki
et
al
report
overal
mortal
rate
mortal
rate
patient
refer
hospit
exclud
seri
show
similar
mortal
rate
one
quefatieh
et
al
report
hospit
mortal
rate
eight
patient
aip
main
reason
observ
differ
mortal
rate
may
patient
underw
surgic
lung
biopsi
receiv
corticosteroid
therapi
quit
earli
cours
diseas
median
hospit
day
day
respect
may
abrog
sever
fibroprolif
respons
irrevers
architectur
distort
occur
patholog
featur
patient
support
find
nonsurvivor
one
patient
residu
fibrosi
show
markedli
increas
fibroprolif
reaction
sever
architectur
distort
fig
bottom
left
e
bottom
right
f
compar
survivor
without
residu
fibrosi
fig
top
left
top
right
b
middl
left
c
middl
right
interestingli
patient
aip
seri
similar
prognos
patient
also
underw
surgic
lung
biopsi
earlier
time
report
studi
day
tabl
role
corticosteroid
treatment
aip
controversi
corticosteroid
inhibit
product
number
proinflammatori
mediat
cytokin
chemokin
oxygen
radic
eicosanoid
complement
product
thought
involv
pathogenesi
aip
therapi
corticosteroid
also
inhibit
fibrot
respons
may
benefici
aip
patient
olson
et
al
analyz
impact
corticosteroid
therapi
patient
surviv
seri
aip
patient
found
associ
dra
matic
respons
corticosteroid
aip
patient
report
isol
case
patient
seri
quefatieh
et
al
receiv
corticosteroid
prompt
author
suggest
earlier
frequent
use
corticosteroid
may
favor
influenc
outcom
patient
aip
chose
use
puls
steroid
therapi
follow
prolong
administr
corticosteroid
knowledg
report
first
one
use
standard
corticosteroid
regimen
aip
patient
puls
steroid
therapi
report
effect
patient
fulmin
lupu
pneumon
domingopedrol
cowork
report
success
treatment
patient
lupu
pneumon
administr
mgd
methylprednisolon
day
follow
mg
prednisolon
also
freter
cowork
use
mgd
methylprednisolon
day
follow
mg
prednisolon
patient
sinc
lung
injuri
seen
aip
patient
also
immunemedi
similar
sever
seen
patient
fulmin
lupu
pneumon
use
compar
dose
drug
patient
ichikado
et
al
use
similar
steroid
regimen
treat
aip
patient
puls
steroid
therapi
also
report
effect
lower
dosag
steroid
patient
sever
acut
respiratori
syndrom
treat
patient
suspect
aip
practic
investig
extens
rule
respiratori
infect
etiolog
respiratori
failur
blood
sputum
cultur
serolog
test
legionella
pneumophila
mycoplasma
pneumonia
chlamydia
pneumonia
perform
bal
done
stain
cultur
bal
fluid
bacteri
organ
acidfast
bacilli
pneumocysti
carinii
virus
respiratori
syncyti
viru
adenoviru
influenza
viru
parainfluenza
viru
herp
simplex
viru
herp
zoster
viru
cytomegaloviru
also
lung
tissu
obtain
surgic
lung
biopsi
process
tissu
cultur
immunostain
cytomegaloviru
herp
simplex
viru
adenoviru
result
microbiolog
studi
extens
review
patient
rule
infect
patient
sever
condit
necessit
initi
steroid
therapi
result
microbiolog
studi
report
two
patient
steroid
therapi
initi
bal
perform
everi
patient
bal
perform
within
h
initi
steroid
therapi
use
approach
possibl
patient
atyp
pneumonia
might
expos
steroid
due
difficulti
diagnos
atyp
pneumonia
includ
viral
pneumonia
viral
cultur
tricki
slow
grow
special
studi
lung
specimen
take
time
serolog
diagnosi
could
take
week
confirm
fact
origin
patient
dad
patient
dad
infecti
origin
receiv
steroid
puls
therapi
due
unexplain
rapid
progress
lung
infiltr
previous
healthi
individu
confirm
presenc
dad
biopsi
specimen
neg
cultur
find
legionella
pneumonia
later
diagnos
one
patient
fourfold
increas
antibodi
titer
three
patient
later
found
posit
adenoviru
immunostain
lung
specimen
two
patient
posit
adenoviru
immunostain
die
reflect
real
clinic
situat
clinician
face
difficult
decis
whether
institut
potenti
harm
therapi
occurr
irrev
slbx
surgic
lung
biopsi
admlbx
time
interv
admiss
lung
biopsi
tx
treatment
na
avail
see
tabl
abbrevi
use
text
known
three
patient
known
one
patient
ibl
damag
vital
organ
case
lung
think
earli
institut
treatment
may
import
improv
prognosi
aip
patient
overal
manag
approach
benefici
patient
whole
surviv
rate
besid
therapi
corticosteroid
includ
puls
therapi
use
treat
differ
viral
pneumonia
especi
lifethreaten
mechan
ventil
caus
lung
injuri
alveolar
overdistens
cyclic
collaps
reopen
alveolar
unit
occur
tidal
breath
minim
ventilatorassoci
lung
injuri
lungprotect
strategi
propos
patient
ard
emphas
need
open
lung
keep
lung
open
avoid
alveolar
overdistens
wide
accept
use
low
tidal
volum
limit
airway
pressur
alveolar
overdistens
improv
surviv
patient
acut
lung
injuri
although
clinic
use
therapi
high
peep
patient
alreadi
receiv
ventil
low
tidal
volum
question
improv
surviv
ard
patient
last
year
thought
reflect
chang
ventilatori
approach
patient
institut
earli
standard
approach
ventil
acut
lung
injuri
patient
low
tidal
volum
ie
mlkg
moder
level
peep
thu
patient
receiv
mechan
ventil
manner
may
contribut
favor
outcom
seen
seri
tidal
volum
data
tabl
calcul
measur
bodi
weight
known
higher
predict
bodi
weight
use
acut
respiratori
distress
syndrom
network
western
countri
tidal
volum
use
patient
may
slightli
higher
use
lower
tidal
volum
group
acut
respiratori
distress
syndrom
network
studi
still
lower
use
higher
tidal
volum
group
also
patient
peak
airway
pressur
good
surrog
plateau
pressur
sinc
patient
ventil
pressurelimit
ventil
cm
h
least
time
surgic
lung
biopsi
perform
suggest
overstretch
alveoli
minim
possibl
evalu
contribut
ventilatori
approach
mortal
patient
base
data
alon
possibl
explan
differ
mortal
rate
observ
seri
compar
seri
one
explan
may
sampl
error
due
rel
small
size
sampl
possibl
patient
whose
lung
less
sever
injur
might
preferenti
includ
studi
rare
diseas
aip
difficult
larg
number
patient
studi
aip
also
number
patient
compar
studi
also
patient
sever
ill
evidenc
low
pao
fio
ratio
high
respir
rate
thu
unlik
differ
mortal
seen
patient
due
entir
factor
also
imposs
rule
patient
sever
aip
might
die
reach
hospit
could
undergo
openlung
biopsi
due
sever
condit
limit
retrospect
design
studi
previou
studi
aip
well
adequ
address
prospect
studi
perform
summari
report
favor
manag
outcom
aip
patient
includ
prompt
investig
respiratori
infect
potenti
etiolog
ard
applic
mechan
ventil
lungprotect
strategi
rapid
confirmatori
diagnosi
dad
surgic
lung
biopsi
earli
initi
highdos
steroid
puls
therapi
result
suggest
earli
intervent
may
improv
clinic
outcom
patient
aip
